DE69231627D1 - Behandelte apatitteilchen für die bilderzeugung in der medizinischen diagnostik - Google Patents

Behandelte apatitteilchen für die bilderzeugung in der medizinischen diagnostik

Info

Publication number
DE69231627D1
DE69231627D1 DE69231627T DE69231627T DE69231627D1 DE 69231627 D1 DE69231627 D1 DE 69231627D1 DE 69231627 T DE69231627 T DE 69231627T DE 69231627 T DE69231627 T DE 69231627T DE 69231627 D1 DE69231627 D1 DE 69231627D1
Authority
DE
Germany
Prior art keywords
imaging
apatite particles
disclosed
magnetic resonance
diagnostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69231627T
Other languages
English (en)
Other versions
DE69231627T2 (de
Inventor
A Deutsch
F Deutsch
P Cacheris
P Ralston
H White
R Woulfe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Inc
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Application granted granted Critical
Publication of DE69231627D1 publication Critical patent/DE69231627D1/de
Publication of DE69231627T2 publication Critical patent/DE69231627T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/225—Microparticles, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/183—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an inorganic material or being composed of an inorganic material entrapping the MRI-active nucleus, e.g. silica core doped with a MRI-active nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1842—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a phosphate or a phosphonate, not being a phospholipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
    • A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
    • A61B2090/3925—Markers, e.g. radio-opaque or breast lesions markers ultrasonic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
    • A61B2090/3954—Markers, e.g. radio-opaque or breast lesions markers magnetic, e.g. NMR or MRI
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/701—Integrated with dissimilar structures on a common substrate
    • Y10S977/72—On an electrically conducting, semi-conducting, or semi-insulating substrate
    • Y10S977/722—On a metal substrate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/88—Manufacture, treatment, or detection of nanostructure with arrangement, process, or apparatus for testing
    • Y10S977/881—Microscopy or spectroscopy, e.g. sem, tem
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908—Mechanical repair performed/surgical
    • Y10S977/91—Strengthening cell or tissue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent
    • Y10S977/928—X-ray agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent
    • Y10S977/929—Ultrasound contrast agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent
    • Y10S977/93—MRI contrast agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
DE69231627T 1991-10-22 1992-10-21 Behandelte apatitteilchen für die bilderzeugung in der medizinischen diagnostik Expired - Fee Related DE69231627T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78432591A 1991-10-22 1991-10-22
US07/948,540 US5344640A (en) 1991-10-22 1992-09-22 Preparation of apatite particles for medical diagnostic imaging
PCT/US1992/009032 WO1993007905A2 (en) 1991-10-22 1992-10-21 Treated apatite particles for medical diagnostic imaging

Publications (2)

Publication Number Publication Date
DE69231627D1 true DE69231627D1 (de) 2001-02-08
DE69231627T2 DE69231627T2 (de) 2001-04-26

Family

ID=27120269

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69231627T Expired - Fee Related DE69231627T2 (de) 1991-10-22 1992-10-21 Behandelte apatitteilchen für die bilderzeugung in der medizinischen diagnostik

Country Status (9)

Country Link
US (4) US5344640A (de)
EP (1) EP0610333B1 (de)
JP (1) JPH07500823A (de)
AT (1) ATE198423T1 (de)
AU (2) AU674291B2 (de)
CA (1) CA2120130A1 (de)
DE (1) DE69231627T2 (de)
ES (1) ES2152932T3 (de)
WO (1) WO1993007905A2 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3231768B2 (ja) * 1991-09-17 2001-11-26 ソーナス ファーマシューティカルス，インコーポレイテッド 気体状超音波造影剤及び超音波造影剤として使用する気体の選定方法
MX9205298A (es) * 1991-09-17 1993-05-01 Steven Carl Quay Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido
US5560902A (en) * 1991-10-22 1996-10-01 Mallinckrodt Medical, Inc. Microfluidization of radioactive calcium/oxyanion-containing particles
US5407659A (en) * 1991-10-22 1995-04-18 Mallinckrodt Medical, Inc. Treated calcium/oxyanion-containing particles for medical diagnostic imaging
US5401492A (en) * 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
CA2154590C (en) * 1993-01-25 2001-06-12 Steven C. Quay Phase shift colloids as ultrasound contrast agents
IL108416A (en) 1993-01-25 1998-10-30 Sonus Pharma Inc Colloids with phase difference as contrast ultrasound agents
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
JPH0797340A (ja) * 1993-06-03 1995-04-11 Terumo Corp Ｍｒｉ造影剤組成物
AU6766494A (en) * 1994-04-11 1995-10-30 Mallinckrodt Medical, Inc. Microfluidization of calcium/oxyanion-containing particles
DE19500665A1 (de) * 1995-01-12 1996-07-18 Axel Prof Dr Haase Verfahren zur ortsauflösenden Abbildung eines Bereiches eines biologischen Objektes mit Hilfe elektromagnetischer Strahlen unter Applikation von Kontrastmittel
US5520904A (en) * 1995-01-27 1996-05-28 Mallinckrodt Medical, Inc. Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
KR100281815B1 (ko) * 1995-07-12 2001-02-15 마루오 기헤이 합성수지용첨가제및합성수지조성물
HU226714B1 (en) * 1996-03-05 2009-07-28 Acusphere Microencapsulated fluorinated gases for use as imaging agents
DE29608321U1 (de) * 1996-05-08 1996-08-08 Aesculap Ag Markierungselement
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6106473A (en) * 1996-11-06 2000-08-22 Sts Biopolymers, Inc. Echogenic coatings
US7229413B2 (en) * 1996-11-06 2007-06-12 Angiotech Biocoatings Corp. Echogenic coatings with overcoat
JP3986564B2 (ja) * 1996-12-27 2007-10-03 丸尾カルシウム株式会社 合成樹脂組成物
US8668737B2 (en) 1997-10-10 2014-03-11 Senorx, Inc. Tissue marking implant
AU4067999A (en) * 1998-04-03 1999-10-25 Du Pont Pharmaceuticals Company Inorganic material for radioactive drug delivery
US5921933A (en) * 1998-08-17 1999-07-13 Medtronic, Inc. Medical devices with echogenic coatings
US5980863A (en) * 1998-11-02 1999-11-09 Eagle Vision Pharmaceutical Corporation Manganese compositions and methods for MRI
US6203778B1 (en) 1998-12-08 2001-03-20 The Regents Of The University Of California Particulate radiopaque contrast agent for diagnostic imaging and microvascular characterization
US6862470B2 (en) 1999-02-02 2005-03-01 Senorx, Inc. Cavity-filling biopsy site markers
US7651505B2 (en) 2002-06-17 2010-01-26 Senorx, Inc. Plugged tip delivery for marker placement
US8361082B2 (en) 1999-02-02 2013-01-29 Senorx, Inc. Marker delivery device with releasable plug
US9820824B2 (en) 1999-02-02 2017-11-21 Senorx, Inc. Deployment of polysaccharide markers for treating a site within a patent
US8498693B2 (en) 1999-02-02 2013-07-30 Senorx, Inc. Intracorporeal marker and marker delivery device
US20090030309A1 (en) 2007-07-26 2009-01-29 Senorx, Inc. Deployment of polysaccharide markers
US7983734B2 (en) 2003-05-23 2011-07-19 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US6575991B1 (en) 1999-06-17 2003-06-10 Inrad, Inc. Apparatus for the percutaneous marking of a lesion
ES2409758T3 (es) 2000-11-20 2013-06-27 Senorx, Inc. Marcadores de sitios tisulares para formación de imagen in vivo
EP1390078A4 (de) * 2001-04-26 2005-10-26 Analogic Corp Ct-scanner für die darstellung eines vorab festgelegten teils eines patienten
US6975896B2 (en) 2002-05-23 2005-12-13 Koninklijke Philips Electronics N.V. Fiducial markers for MRI
US20060036158A1 (en) 2003-11-17 2006-02-16 Inrad, Inc. Self-contained, self-piercing, side-expelling marking apparatus
WO2004050168A2 (en) * 2002-11-27 2004-06-17 Board Of Regents, The University Of Texas System Radiopharmaceuticals and radioactive microspheres for locoregional ablation of abnormal tissues
US20040170692A1 (en) * 2003-02-12 2004-09-02 The Curators Of The University Of Missouri Calcium phosphate bodies and a process for making calcium phosphate bodies
US7877133B2 (en) 2003-05-23 2011-01-25 Senorx, Inc. Marker or filler forming fluid
US7081366B2 (en) * 2003-06-02 2006-07-25 Northrop Grumman Corporation Uniform bead dosing from a stable dispersion
US20050273002A1 (en) 2004-06-04 2005-12-08 Goosen Ryan L Multi-mode imaging marker
AU2005215234B2 (en) * 2004-02-20 2009-02-19 Algeta As Alpha-emitting Hydroxyapatite particles
CN100427142C (zh) * 2005-01-10 2008-10-22 重庆海扶(Hifu)技术有限公司 一种高强度聚焦超声治疗用助剂及其筛选方法
CN100574810C (zh) * 2005-01-10 2009-12-30 重庆海扶(Hifu)技术有限公司 一种高强度聚焦超声治疗用质粒类助剂及其应用
US20100041983A9 (en) * 2005-04-04 2010-02-18 Elisha Rabinovitz Device and method for pathology detection
US10357328B2 (en) 2005-04-20 2019-07-23 Bard Peripheral Vascular, Inc. and Bard Shannon Limited Marking device with retractable cannula
US20060293581A1 (en) * 2005-05-12 2006-12-28 Sunnybrook And Women's College Health Sciences Centre Marker device for X-ray, ultrasound and MR imaging
CA2562580C (en) 2005-10-07 2014-04-29 Inrad, Inc. Drug-eluting tissue marker
US7702378B2 (en) 2005-11-17 2010-04-20 Breast-Med, Inc. Tissue marker for multimodality radiographic imaging
US11241296B2 (en) 2005-11-17 2022-02-08 Breast-Med, Inc. Imaging fiducial markers and methods
BRPI0708636A2 (pt) * 2006-03-06 2011-06-07 Symphogen As anticorpo policlonal recombinante para tratamento de infecções por vìrus sinciciais respiratórios
US20070258903A1 (en) * 2006-05-02 2007-11-08 Kleiner Lothar W Methods, compositions and devices for treating lesioned sites using bioabsorbable carriers
GB2442000A (en) * 2006-06-07 2008-03-26 Apatech Ltd Biomedical materials containing gadolinium
US20080038190A1 (en) * 2006-08-11 2008-02-14 Simpson Thomas J Composition apparatus and method for use in imaging
EP3542748B1 (de) 2006-12-12 2023-08-16 C. R. Bard, Inc. Gewebemarker mit mehreren bildgebungsmodi
US8401622B2 (en) 2006-12-18 2013-03-19 C. R. Bard, Inc. Biopsy marker with in situ-generated imaging properties
JP5074803B2 (ja) * 2007-03-30 2012-11-14 ニプロ株式会社 エコー造影可能な金属針
FR2922454B1 (fr) * 2007-10-22 2010-01-01 Biomatlante Substitut osseux comprenant un agent de contraste, son procede de preparation et ses utilisations
US9327061B2 (en) 2008-09-23 2016-05-03 Senorx, Inc. Porous bioabsorbable implant
JP5458231B2 (ja) * 2008-09-30 2014-04-02 ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 フッ素アパタイト粉体の製造方法、フッ素アパタイト粉体および吸着装置
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US20110190662A1 (en) * 2008-10-01 2011-08-04 Beacon Endoscopic Corporation Rapid exchange fna biopsy device with diagnostic and therapeutic capabilities
CA2742765C (en) 2008-12-30 2016-04-12 C.R. Bard Inc. Marker delivery device for tissue marker placement
US20100204570A1 (en) * 2009-02-06 2010-08-12 Paul Lubock Anchor markers
EP2228079A1 (de) * 2009-03-03 2010-09-15 Graftys Galliumdotierte phosphorcalciumhaltige Verbindungen
US8623311B2 (en) * 2009-03-03 2014-01-07 Graftys Gallium-doped phosphocalcic compounds
US8894958B2 (en) * 2009-03-03 2014-11-25 Centre National De La Recherche Scientifique (C.N.R.S.) Galliated calcium phosphate biomaterials
EP2228080A1 (de) * 2009-03-03 2010-09-15 Graftys Galliierte Calciumphosphat-Biomaterialien
US9039784B2 (en) * 2009-07-28 2015-05-26 Southwest Research Institute Micro-structure particles for load bearing bone growth
EP2488100A1 (de) * 2009-10-15 2012-08-22 Koninklijke Philips Electronics N.V. Spektrale magnetpartikelabbildung
WO2011123613A1 (en) * 2010-04-01 2011-10-06 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University A dual ct/mri nanoparticle contrast agent
IT1401487B1 (it) 2010-07-29 2013-07-26 Consiglio Nazionale Ricerche Idrossiapatite intrinsecamente magnetica
US9119887B2 (en) 2010-09-16 2015-09-01 Mo-Sci Corporation Low-density magnesium-aluminum-silicate (MAS) microparticles for radiotherapy and/or radioimaging
US8865123B1 (en) 2010-09-16 2014-10-21 Mo-Sci Corporation Strontium phosphate microparticle for radiological imaging and therapy
US9849200B2 (en) 2010-09-16 2017-12-26 Mo-Sci Corporation Strontium phosphate microparticle for radiological imaging and therapy
WO2014141288A1 (en) 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University The art, method, manner, process and system of a nano-biomineral for multi-modal contrast imaging and drug delivery
WO2014141287A1 (en) 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University The art, method, manner, process and system of multifunctional nanobiomaterial for molecular imaging and drug- delivery
USD716450S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD715942S1 (en) 2013-09-24 2014-10-21 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716451S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD715442S1 (en) 2013-09-24 2014-10-14 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
US9795455B2 (en) 2014-08-22 2017-10-24 Breast-Med, Inc. Tissue marker for multimodality radiographic imaging
US11369681B2 (en) 2015-12-03 2022-06-28 Amrita Vishwa Vidyapeetham Radio-wave responsive doped nanoparticles for image-guided therapeutics

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3505239A (en) * 1966-07-26 1970-04-07 Westinghouse Electric Corp Crystal laser material
US4079124A (en) * 1976-04-21 1978-03-14 Medi-Physics, Inc. Method of preparing X-ray contrast media containing ores of hafnium, tantalum and tungsten
DE2724814C3 (de) * 1977-06-02 1980-03-27 Kulzer & Co Gmbh, 6380 Bad Homburg Vorprodukt fur die Zubereitung von Knochenzement
US4243652A (en) * 1978-07-14 1981-01-06 The Procter & Gamble Company Gastrointestinal scanning agent
US4681119A (en) * 1980-11-17 1987-07-21 Schering Aktiengesellschaft Method of production and use of microbubble precursors
FR2509611B1 (fr) * 1981-07-20 1986-07-18 Fabre Sa Pierre Nouvel agent anti-acide et composition pharmaceutique le contenant
CA1193087A (en) * 1982-04-20 1985-09-10 Thomas E. Peters Ce-mn coactivated fluoroapatite phosphors as the yellow emitting component for high efficacy lamp blends, process for producing same, and a fluorescent lamp containing same
US4657755A (en) * 1982-04-23 1987-04-14 A/S Alfred Benzon Composition and method for investigating alimentary functions
US4635643A (en) * 1982-09-28 1987-01-13 The Medical College Of Wisconsin Research Foundation, Inc. Assay method for the in vivo quantitative determination of mineral content in bone
US4572203A (en) * 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
SE463651B (sv) * 1983-12-21 1991-01-07 Nycomed As Diagnostikum och kontrastmedel
FR2568238B1 (fr) * 1984-07-24 1988-06-24 Centre Nat Rech Scient Apatite de terres rares, procedes de preparation et applications
US4680171A (en) * 1985-03-15 1987-07-14 William Shell Visualization of a bloodstream circulation with biodegradable microspheres
US5186922A (en) * 1985-03-15 1993-02-16 See/Shell Biotechnology, Inc. Use of biodegradable microspheres labeled with imaging energy constrast materials
GB8518300D0 (en) * 1985-07-19 1985-08-29 Amersham Int Plc Contrast agent
GB8522535D0 (en) * 1985-09-11 1985-10-16 Amersham Int Plc Contrast agent
US4709703A (en) * 1985-11-12 1987-12-01 Mayo Foundation Imaging system and method using radiopaque microspheres for evaluation of organ tissue perfusion
DE3542972A1 (de) * 1985-12-05 1987-06-11 Merck Patent Gmbh Pharmakadepot
US4888248A (en) * 1986-07-01 1989-12-19 Hidefumi Hirai Colloidal metal dispersion, and a colloidal metal complex
GB8701054D0 (en) * 1987-01-16 1987-02-18 Amersham Int Plc Contrast agent for nmr scanning
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
US5047031A (en) * 1988-04-20 1991-09-10 Norian Corporation In situ calcium phosphate minerals method
ATE117829T1 (de) * 1988-05-24 1995-02-15 Anagen Uk Ltd Magnetisch anziehbare teilchen und herstellungsverfahren.
JPH0288059A (ja) * 1988-09-26 1990-03-28 Univ Kyoto 温熱療法用セラミックス発熱体及びその製造方法
US5009898A (en) * 1988-09-29 1991-04-23 Kabushiki Kaisha Sangi Antimicrobial hydroxyapatite powders and methods for preparing them
US5055307A (en) * 1988-12-29 1991-10-08 Asahi Kagaku Kogyo Kabushiki Kaisha Slow release drug delivery granules and process for production thereof
US5081997A (en) * 1989-03-09 1992-01-21 Vance Products Incorporated Echogenic devices, material and method
DD291982A5 (de) * 1990-02-12 1991-07-18 ���������`��������`����@����k�� Apatitglaskeramik, vorzugsweise fuer dentale glasionomerzemente
US5236693A (en) * 1990-11-14 1993-08-17 Brigham And Women's Hospital Medical ultrasound contrast agent and method of using same
US5122363A (en) * 1990-12-07 1992-06-16 Board Of Regents, The University Of Texas System Zeolite-enclosed transistion and rare earth metal ions as contrast agents for the gastrointestinal tract
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5179955A (en) * 1991-02-22 1993-01-19 Molecular Biosystems, Inc. Method of abdominal ultrasound imaging
US5330742A (en) * 1991-08-05 1994-07-19 Mallinckrodt Medical, Inc. Methods and compositions for magnetic resonance imaging
US5407659A (en) * 1991-10-22 1995-04-18 Mallinckrodt Medical, Inc. Treated calcium/oxyanion-containing particles for medical diagnostic imaging
US5342609A (en) * 1991-10-22 1994-08-30 Mallinckrodt Medical, Inc. Microfluidization of calcium/oxyanion-containing particles

Also Published As

Publication number Publication date
US5344640A (en) 1994-09-06
AU674291B2 (en) 1996-12-19
US5468465A (en) 1995-11-21
US5690908A (en) 1997-11-25
AU7034596A (en) 1997-01-23
WO1993007905A3 (en) 1993-08-05
DE69231627T2 (de) 2001-04-26
AU686523B2 (en) 1998-02-05
AU2886492A (en) 1993-05-21
ATE198423T1 (de) 2001-01-15
JPH07500823A (ja) 1995-01-26
EP0610333B1 (de) 2001-01-03
ES2152932T3 (es) 2001-02-16
WO1993007905A2 (en) 1993-04-29
CA2120130A1 (en) 1993-04-29
EP0610333A1 (de) 1994-08-17
US5609850A (en) 1997-03-11

Similar Documents

Publication Publication Date Title
DE69231627D1 (de) Behandelte apatitteilchen für die bilderzeugung in der medizinischen diagnostik
Laubenberger et al. Breath‐hold projection magnetic resonance‐cholangio‐pancreaticography (MRCP): a new method for the examination of the bile and pancreatic ducts
Lisle et al. Imaging for students
DE69920425T2 (de) Verwendung von teilchenförmigen kontrastmitteln in der diagnostischen bilderzeugung zur untersuchung physiologischer parameter
Staatz et al. Interstitial T1-weighted MR lymphography: lipophilic perfluorinated gadolinium chelates in pigs
US20090317327A1 (en) Aqueous Dispersion of Superparamagnetic Single-Domain Particles, Production and Use Thereof in Diagnosis and Therapy
Riccabona Potential of modern sonographic techniques in paediatric uroradiology
JPH08509217A (ja) 医療診断イメージング用の処理されたカルシウム／オキシアニオン含有粒子
JP2001512144A (ja) 組織の潅流の造影剤増強磁気共鳴撮像法
Huk et al. Nuclear magnetic resonance (NMR) tomography of the central nervous system: comparison of two imaging sequences
de Verdier et al. MRI of the brachial plexus: a review of 51 cases
Li et al. Magnetic resonance urography by breath‐hold contrast‐enhanced three‐dimensional FISP
Ishikawa et al. Magnetic resonance imaging of the intracranial epidermoid
KR20000005194A (ko) Res기관의t1가중자기공명영상ㅇ형성방법
US20130209369A1 (en) Nanoparticles based on gadoliium coordination polymers as highly sensitive t1 mri contrast agents
Messiaen et al. Hepatic angiomyo (myelo) lipoma: difficulties in radiological diagnosis and interest of fine needle aspiration biopsy
Stoskopf Clinical imaging in zoological medicine: a review
Newell et al. Quantitative magnetic resonance imaging of the normal feline cranial abdomen
JPH10120597A (ja) リンパ節高集積性コロイド粒子
ØKSENDAL et al. Superparamagnetic particles as an oral contrast agent in abdominal magnetic resonance imaging
Davis et al. Nuclear magnetic resonance imaging: current capabilities
Rane et al. Imaging Modalities and Their Applications in Cancer Detection Using Nanomaterials
WO1993010821A1 (en) A method and formulations useful to improve the study of human body cavities
Kuoni et al. Application of magnetic resonance imaging in reptile medicine
Xiong et al. An animal model of corpus callosum impingement as seen in patients with normal pressure hydrocephalus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee